Company research / XTNT

Xtant Medical Holdings, Inc. (XTNT)

CIK 0001453593 · NYSE · Surgical & Medical Instruments & Apparatus

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Xtant Medical Holdings, Inc. reported revenue of $133.93M. Revenue grew 14.2% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $109.53M.

Key ratios (year ended 2025-12-31)

62.9%
Gross margin
5.4%
Operating margin
3.7%
Net margin
9.8%
Return on year-end equity
14.2%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 4 (ownership change) · 2026-08-18

Headquarters locality: Belgrade · View on map

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Stock splits: 1-for-10, first reflected in a filing dated 2014-08-14; 1-for-12, first reflected in a filing dated 2018-04-05. Figures are as filed: per-share figures and share counts last reported before a split are on the old share basis, so changes and growth rates across a split are not shown. Splits are read from the filings' own restatements, so a share conversion in a merger or reorganization shows up the same way.

Period endedTTM to
2026-06-30
2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$109.53M$133.93M$117.27M$91.30M$57.97M$55.26M$53.34M$64.68M$72.20M$82.61Mn/a
Cost of Revenue$44.48M$49.65M$49.05M$35.84M$25.83M$22.77M$18.95M$22.17M$28.72M$32.51M$27.71M
Gross Profit$65.05M$84.27M$68.22M$55.47M$32.14M$32.49M$34.39M$42.52M$43.49M$50.10M$62.29M
R&D Expense$2.22M$2.10M$2.38M$1.34M$915.0K$870.0K$657.0K$932.0K$1.70M$2.44M$3.41M
Operating Income-$10.49M$7.28M-$12.07M-$10.16M-$6.75M-$3.85M-$751.0K-$2.25M-$60.08M-$37.83M-$7.55M
Depreciation & Amortization$4.02M$5.22M$4.22M$3.17M$1.29M$1.33M$2.08M$3.14M$6.59M$8.41M$7.24M
EBITDA-$6.47M$12.51M-$7.85M-$6.98M-$5.46M-$2.52M$1.33M$890.0K-$53.49M-$29.43M-$303.4K
Net Income-$11.14M$4.97M-$16.45M$660.0K-$8.48M-$4.85M-$7.02M-$8.22M-$70.10M-$52.41M-$19.49M
EPS (Diluted)n/a$0.03-$0.12$0.01-$0.09-$0.06-$0.25-$0.63-$5.97-$34.76-$18.46
Total Assets$79.67M$94.14M$93.84M$92.61M$60.23M$54.69M$41.47M$43.16M$46.42M$105.70M$144.10M
Total Liabilities$39.65M$43.19M$50.87M$41.26M$26.06M$23.81M$26.95M$87.36M$90.19M$164.40M$151.17M
Long-Term Debt$7.29M$11.03M$22.04M$17.17M$9.69M$11.79Mn/a$76.24M$77.94M$137.96M$119.22M
Shareholders' Equity$40.02M$50.95M$42.96M$51.35M$34.17M$30.88M$14.51M-$44.20M-$43.77M-$58.70M-$7.07M
Cash & Equivalents$9.87M$17.05M$6.20M$5.71M$20.30M$18.24M$2.34M$5.24M$6.80M$2.86M$2.58M
Operating Cash Flow$570.0K$12.55M-$11.90M-$9.52M-$5.34M$439.0K-$731.0K-$413.0K$1.21M-$543.0K-$14.41M
Capital Expenditures$1.27M$2.38M$4.11M$1.46M$1.76M$2.12M$1.54M$879.0K$624.0K$1.64M$5.83M
Free Cash Flow-$696.0K$10.16M-$16.01M-$10.97M-$7.11M-$1.68M-$2.28M-$1.29M$588.0K-$2.18M-$20.24M
Shares Outstanding140.26M140.04M139.05M130.18M108.87M87.07M77.57M13.16M13.17M1.51M1.44M
Weighted Average Diluted Sharesn/a150.04M133.67M126.79M94.09M85.46M28.50M13.16M11.74M1.51M1.06M
EPS (Basic)n/a$0.04-$0.12$0.01-$0.09-$0.06-$0.25-$0.63-$5.97-$34.76-$18.46

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView